Home
News
Create
Screeners
Insights
Prism Medico & Pharmacy
29.
30
+0.30
(+1.03%)
Market Cap
₹39.71 Cr
PE Ratio
126.09
Industry
Financial Services
Buy
Sell
Company Performance:
1D
+1.03%
1M
-2.88%
6M
+58.38%
1Y
+85.68%
5Y
+193.29%
View Company Insights
Latest news about Prism Medico & Pharmacy
Prism Medico reports net profit of ₹31.84 lakh in FY26
4 days ago
Prism Medico and Pharmacy Limited reported a net profit of ₹31.84 lakh for the financial year ended March 31, 2026, reversing the net loss of ₹4.87 lakh recorded in the previous year. Revenue from operations surged to ₹244.34 lakh in FY26 from ₹63.19 lakh in FY25, driven primarily by the sale of pharmaceutical products. The board approved the audited standalone financial results at its meeting held on May 28, 2026. The statutory auditors, Garg Mendiratta & Associates, issued an unmodified opinion on the financial statements.
Prism Medico & Pharmacy Appoints Mr. Harpreet Singh as Internal Auditor for FY 2025-2026
May 11, 2026
Prism Medico and Pharmacy Allots 75,00,000 Equity Shares and 50,00,000 Convertible Warrants on Preferential Basis
May 05, 2026
Prism Medico and Pharmacy Limited Submits Q4FY26 Compliance Certificate to Stock Exchanges
Apr 14, 2026
Prism Medico and Pharmacy Limited Reports No Promoter Share Encumbrance in FY26
Apr 08, 2026
More news about Prism Medico & Pharmacy
08
Apr 26
Prism Medico and Pharmacy Limited Confirms No Non-Convertible Securities Issued for Q4FY26
Prism Medico and Pharmacy Limited filed a regulatory intimation on 06/04/2026 under SEBI LODR Regulation 57(5), confirming it has not issued any non-convertible securities. The company reported no interest, dividend, or principal payment obligations during Q4FY26 (01st January to 31st March, 2026). The filing was submitted to BSE Limited and Metropolitan Stock Exchange of India Limited, signed by Director Davender Singh.
07
Apr 26
Prism Medico Files Regulatory Compliance for Non-Convertible Securities Q4 FY26
Prism Medico and Pharmacy Limited has maintained its regulatory compliance by filing intimations under different SEBI regulations regarding non-convertible securities. The latest filing under Regulation 57(5) confirms no securities were issued for Q4 FY26, while a previous filing under Regulation 57(4) addressed payable obligations for Q1 FY27.
31
Mar 26
Prism Medico and Pharmacy Limited Clarifies Stock Price Movement Under SEBI Regulation 30
Prism Medico and Pharmacy Limited issued a regulatory clarification on February 27, 2026, addressing significant stock price movements to BSE and MSEI exchanges. The company attributed price fluctuations to market conditions and speculation, confirming all material information has been properly disclosed under SEBI regulations. Management emphasized that promoters and key personnel have not traded in company securities recently and reiterated commitment to ongoing transparency.
25
Mar 26
Prism Medico Submits Scrutinizer's Report with 99.98% EGM Approval Results
Prism Medico and Pharmacy Limited has submitted the scrutinizer's report for its March 20, 2026 EGM, revealing 99.98% shareholder approval for both special business resolutions. The company received overwhelming support from 43 voters casting 3,76,133 votes for the alteration of Articles of Association and preferential issue of equity shares and convertible warrants, enabling the company to proceed with its ₹25.00 crore fundraising plan for pharmaceutical manufacturing expansion and infrastructure development.
23
Feb 26
Prism Medico and Pharmacy Board Approves Rs. 25 Crore Equity Fundraising Through Preferential Issue
Prism Medico and Pharmacy Limited's board approved a Rs. 25 crore fundraising through preferential allotment of 75 lakh equity shares and 50 lakh convertible warrants at Rs. 20 each on February 23, 2026. The board also amended Articles of Association to facilitate future securities issuance and scheduled an EGM for March 20, 2026, for shareholder approval. The allocation covers both promoter and non-promoter categories with detailed investor-wise distribution already finalized.
13
Feb 26
Prism Medico Reports Q3FY26 Loss of ₹1.34 Lakhs, Revenue Drops to ₹7.10 Lakhs
Prism Medico and Pharmacy Limited announced Q3FY26 financial results showing net loss of ₹1.34 lakhs compared to ₹0.96 lakhs loss in Q3FY25, with revenue declining significantly to ₹7.10 lakhs from ₹20.86 lakhs year-on-year. However, the company's year-to-date performance demonstrates profitability with net profit of ₹55.91 lakhs on total income of ₹218.60 lakhs for the nine-month period.
14
Jan 26
Prism Medico and Pharmacy Limited Submits SEBI Depositories Compliance Certificate for Q3FY26
Prism Medico and Pharmacy Limited submitted its Q3FY26 confirmation certificate under SEBI Depositories Regulations for the quarter ended December 31, 2025. The filing, made on January 14, 2026, through RTA Purva Sharegistry, confirms no dematerialisation activity occurred during the quarter. The company maintains compliance with regulatory requirements across BSE and MSEI exchanges.
21
Nov 25
Prism Medico Reports Q2 Loss Amid Revenue Decline, Corrects Financial Statement Filing
Prism Medico & Pharmacy reported a net loss of ₹0.10 crore for Q2 ended September 30, with revenue declining 68.75% to ₹0.50 crore. Despite the quarterly loss, the company posted a half-year profit of ₹57.25 lakh. The operating profit margin fell to -20.00% from 40.88% in the previous quarter. The company also re-uploaded its complete financial statements to stock exchanges, addressing an initial filing error.
12
Sept 25
Prism Medico & Pharmacy Limited Reports Remarkable Q1 Performance with ₹65.73 Lakh Net Profit
Prism Medico & Pharmacy Limited announced a significant financial turnaround in Q1. Revenue from operations increased to ₹158.87 lakhs from ₹7.28 lakhs in the previous quarter. Net profit reached ₹65.73 lakhs, compared to ₹4.15 lakhs in Q4 and a loss of ₹9.00 lakhs year-over-year. The company demonstrated improved operational efficiency and cost management despite the revenue surge. The Board of Directors approved these unaudited standalone financial results, which were reviewed by auditors and submitted to stock exchanges in compliance with SEBI regulations.
Prism Medico & Pharmacy
29.
30
+
0.
30
(+
1.
03
%)
1 Year Returns:
+85.68%
Industry Peers
Bajaj Finance
880.65
(-
0.
94
%)
Shriram Finance
913.15
(-
0.
64
%)
Jio Financial Services
238.05
(+
1.
32
%)
Muthoot Finance
3,240.30
(-
0.
19
%)
Cholamandalam Investment
1,486.40
(-
0.
44
%)
SBI Cards
606.60
(-
1.
52
%)
Sundaram Finance
4,296.80
(+
1.
99
%)
M&M Financial Services
295.55
(+
0.
15
%)
Authum Inv & Infr
454.00
(-
0.
86
%)
Poonawalla Fincorp
395.20
(+
0.
75
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar